Clinical trial · Observational
Impact of Congenital Heart Disease on the Prognosis of Childhood Hematological Neoplasms: A Multicenter Cohort Study
Impact of Congenital Heart Disease on Quality of Life and Long-Term Outcomes in Childhood Hematological Tumor Survivors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to determine whether congenital heart disease increases chronic health risks and mortality in childhood hematological tumor survivors, explore potential shared genetic factors between these conditions, identify other factors affecting long-term outcomes and quality of life, and validate any discovered genetic links through mechanistic investigations.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Congenital Heart Disease (CHD) | — | UNRESOLVED | — |
| Hematologic Malignancy | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Cohort of pediatric patients with congenital heart disease and hematological tumors
- label
- Cohort of pediatric patients with hematological tumors
Primary outcomes (2)
- measure
- Occurrence of all-cause death
- timeFrame
- from enrollment to follow-up for 5 year
- measure
- Frequency and severity of SAEs assessed by CTCAE v5.0
- timeFrame
- from enrollment to follow-up for 5 year
- description
- CommonTerminology Criteria for Adverse Events（CTCAE）has 5 levels of AE determination, increasing in severity as the level increases
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 0 Weeks
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Children with hematologic malignancies diagnosed by pathology or bone marrow aspiration/biopsy at member hospitals of the Hematologic Oncology Specialty Alliance between 2010 and 2025; 2. Aged 0-17 years at diagnosis, regardless of gender; 3. Completed standard treatment for hematologic malignancies and confirmed diagnosis of congenital heart disease by cardiac ultrasound and clinical evaluation; 4. Written informed consent can be provided by the child or their legal guardian. Exclusion Criteria: 1. Presence of birth defects other than congenital heart disease; 2. Other serious cardiac conditions, malignancies, or comorbidities that may interfere with study results; 3. Inability to provide the information and data required for the study.
References
Publications (0)
Data not yet available